$300.150
-5.973 (-1.99%)終値時点
CRL のニュース
CRL のイベント
Charles River Laboratories Partners with Magellan Stem Cells for Therapy Development
Charles River Laboratories and Magellan Stem Cells announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River's specialized expertise in biologics quality control, current Good Manufacturing Practice viral and release testing, and extensive development support services.
Charles River Laboratories and Autolomous Launch Apollo Orchestrate
Charles River Laboratories International and Autolomous announced the launch of Apollo Orchestrate, a new capability within Charles River's Apollo platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE digital Laboratory Execution System. Apollo Orchestrate marks a significant milestone in the Company's broader, ongoing transition toward a fully digital laboratory experience which is connected, compliant, and scalable. "Biological testing ensures that a medicine is safe, effective, and ready for patients, but data collection and management across fragmented, often manual and paper-based systems from R&D to commercial release create unnecessary delays for patients, opportunities for errors, audit risks, and lost revenue," said Alexander Seyf, CEO of Autolomous. "We designed autoloMATE to enable life sciences companies to connect that data directly into an integrated, digitized workflow and increase speed, accuracy, and cost-effectiveness."
PMGC Holdings Subsidiary Signs Statement of Work with Charles River Laboratories
PMGC Holdings (PMGC) announced that its subsidiary, NorthStrive Biosciences has executed a Statement of Work with Charles River Laboratories (CRL) to conduct analytical characterization supporting the development of NorthStrive Biosciences' EL-22 and EL-32 engineered probiotic programs. Under the SOW, Charles River will perform specialized analytical testing designed to characterize plasmid copy numbers in NorthStrive's engineered bacterial product candidates.
Everpure Stock Rises $20.86 to $130.51
Notable gainers among liquid option names this morning include Everpure, Inc (P) $130.51 +20.86, Charles River (CRL) $293.77 +16.44, Kroger (KR) $59.45 +1.80, PerkinElmer Inc (RVTY) $146.41 +4.30, and Ralph Lauren (RL) $347.50 +10.03.
Charles River Laboratories Confirms Revenue Growth Target
Consensus $11.33. Reaffirms revenue growth at upper end of 0%-1%; non-GAAP operating margin 21%-21.3%. Charles River Laboratories International will host its 2026 Investor Day. Birgit Girshick, CEO, along with members of the senior management team, will highlight a refreshed strategic vision, Pathway to Purpose, to modernize the Company, strengthen its scientific portfolio, and drive profitable growth to enhance long-term shareholder value creation. Pathway to Purpose is centered on three strategic initiatives: Modernizing the Company to Drive Greater Productivity and Efficiency: Through its recently introduced Create the Future program, Charles River expects to generate over $300M in cumulative savings from 2027 through 2030 by simplifying processes and increasing automation and digital enablement. The Company will expand its use of AI-assisted digital tools to improve operating efficiency, reduce drug development timelines, and enhance client satisfaction. Strengthening a World-Class Scientific Portfolio: Charles River will expand its innovative scientific capabilities through organic and inorganic investments. Priority investment areas include bioanalysis, in vitro testing, and related scientific solutions. Charles River expects its bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450M in 2030. Delivering a Customized, Client-Centric Approach: The Company's client-centric approach will further enable it to capitalize on improving biopharmaceutical R&D demand, growth in biologics and complex modalities, the potential benefit of AI-assisted drug discovery, and the increasing complexity of scientific research. Charles River is expanding its Apollo cloud-based platform to create a more seamless client experience. Apollo(TM) now serves more than 18,000 client users through its scientific decision-support and e-commerce capabilities and was recently expanded to support Manufacturing Solutions' clients.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。